Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Myasthenia Gravis
Pharma
Argenx's Vyvgart posts ph. 3 win in ocular myasthenia gravis
Already on a roll with Vyvgart, argenx has posted trial results that could allow for it to reach a new indication—ocular myasthenia gravis.
Kevin Dunleavy
Feb 26, 2026 11:18am
Argenx telegraphs CEO switch as chief drug Vyvgart rolls ahead
Jan 5, 2026 2:12pm
Amgen nabs FDA nod for Uplizna in generalized myasthenia gravis
Dec 12, 2025 9:49am
Argenx lays out details on Vyvgart's seronegative gMG win
Oct 29, 2025 2:34pm
J&J's Imaavy comes up short in rheumatoid arthritis study
Aug 29, 2025 10:56am
Argenx pursues Vyvgart nod in seronegative myasthenia gravis
Aug 25, 2025 11:38am
